Agios Pharmaceuticals (AGIO) Cash & Equivalents (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Cash & Equivalents data on file, last reported at $99.6 million in Q2 2026.

• Quarterly Cash & Equivalents rose 23.22% year-over-year to $99.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $99.6 million (up 23.22% YoY) and the FY2025 annual result came in at $89.1 million, up 16.9% from the prior year.
• Cash & Equivalents eased to $99.6 million in Q2 2026, from $113.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $253.7 million in Q3 2024 to a low of $64.3 million in Q3 2023.
• A 5-year average of $103.3 million and a median of $88.8 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 95.76% — and 2024, when it soared 294.4%.
• Tracing AGIO's Cash & Equivalents over 5 years: stood at $139.3 million in 2022, then slumped by 36.66% to $88.2 million in 2023, then declined by 13.56% to $76.2 million in 2024, then climbed by 16.9% to $89.1 million in 2025, then climbed by 11.8% to $99.6 million in 2026.
• The last three Cash & Equivalents figures came in at $99.6 million (Q2 2026), $113.6 million (Q1 2026), and $89.1 million (Q4 2025), per Business Quant data.